{
    "clinical_study": {
        "@rank": "137758", 
        "arm_group": [
            {
                "arm_group_label": "Sequence 1", 
                "arm_group_type": "Experimental", 
                "description": "Subjects randomized to Sequence 1 will receive Treatment A followed by Treatment B. Treatment A is a single 2 mg oral dose of midazolam alone. Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991 and a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose."
            }, 
            {
                "arm_group_label": "Sequence 2", 
                "arm_group_type": "Experimental", 
                "description": "Subjects randomized to Sequence 2 will receive Treatment B followed by Treatment A with a washout of no less than 14 days in between.Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991 and a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose. There will be a minimum washout of 14 days prior to beginning Treatment A. Treatment A is a single 2 mg oral dose of midazolam alone."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a drug-drug interaction study to compare the pharmacokinetics of a 2 mg oral dose of\n      midazolam in adult healthy women of non-childbearing potential when administered alone and\n      when administered along with 8 daily 125 mg doses of PD-0332991. Volunteers will be\n      randomized to one of two sequences. Volunteers in sequence 1 will receive midazolam alone in\n      treatment period 1, followed by multiple dose PD-0332991 and midazolam in treatment period\n      2. Volunteers randomized to sequence 2 will receive multiple dose PD-0332991 and midazolam\n      in treatment period 1, and following a washout period of no less than 14 days they will\n      receive midazolam alone in treatment period 2."
        }, 
        "brief_title": "A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy females of non-child bearing potential between the ages of 18 and 65 years\n             old.\n\n          -  A Body Mass Index (BMI) of 17.5 to 32.0 kg/m2 and a total body weight >50 kg (110\n             lbs).\n\n          -  A signed informed consent document.\n\n        Exclusion Criteria:\n\n          -  Any evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease.\n\n          -  A positive urine drug screen.\n\n          -  Pregnant or nursing females.\n\n          -  Treatment with an investigational drug within 30 days or 5 half-lives of the first\n             dose of study medication."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01756781", 
            "org_study_id": "A5481012"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sequence 1", 
                "description": "Treatment A includes a single 2 mg oral dose of midazolam alone. Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.", 
                "intervention_name": "Midazolam", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sequence 1", 
                "description": "Treatment B includes 8 daily 125 mg oral doses of PD-0332991.", 
                "intervention_name": "PD-0332991", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sequence 2", 
                "description": "Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.\nTreatment A includes a single 2 mg oral dose of midazolam alone.", 
                "intervention_name": "Midazolam", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sequence 2", 
                "description": "Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991.", 
                "intervention_name": "PD-0332991", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Midazolam"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "PD-0332991", 
            "Midazolam", 
            "Drug-Drug Interaction Study", 
            "Healthy Adult Volunteer"
        ], 
        "lastchanged_date": "December 16, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5481012&StudyName=A%20Drug-Drug%20Interaction%20Study%20To%20Investigate%20The%20Potential%20For%20Multiple%20Doses%20Of%20Palbociclib%20%28PD-0332991%29%20To%20Alter%20The%20Pharmacokinetics%"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "South Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33143"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Randomized, Open-Label, 2-Sequence, 2-Period Crossover Study Of The Effect Of Multiple Doses Of PD-0332991 On Midazolam Pharmacokinetics In Healthy Women of Non-Childbearing Potential", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).", 
            "measure": "Midazolam Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]", 
            "safety_issue": "No", 
            "time_frame": "0-36hrs post midazolam dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01756781"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Midazolam Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "0-36 hrs post midazolam dose"
            }, 
            {
                "measure": "Maximum Observed Plasma Midazolam Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0-36 hrs post midazolam dose"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Midazolam Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0-36 hrs post midazolam dose"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2) of Midazolam", 
                "safety_issue": "No", 
                "time_frame": "0-36 hrs post midazolam dose"
            }, 
            {
                "measure": "Minimum Observed Plasma Trough Concentration (Cmin) of PD-0332991", 
                "safety_issue": "No", 
                "time_frame": "Prior to the 6th, 7th, and 8th oral daily PD-0332991 dose"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}